ReviewFrontiers in cell and developmental biology2020
Limited Potential or Unfavorable Manipulations? Strategies Toward Efficient Mesenchymal Stem/Stromal Cell Applications.
Review in Frontiers in cell and developmental biology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 37 citations in OpenAlex.
- Berberine Improved the Therapeutic Efficacy of UC-MSCs for DSS-Induced Colitis via Aerobic Glycolysis.Phytotherapy research : PTR · 2026Article
- Engineering Approaches to Modify Immunomodulatory Functions of Mesenchymal Stromal Cells (MSCs): Tissue Regeneration and Clinical Application.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Review
- The influence of cell source on the senescence of human mesenchymal stem/stromal cells.Human cell · 2025Review
- Identification of critical process parameters and quality attributes for bioreactor-based expansion of human MSCs.Frontiers in bioengineering and biotechnology · 2025Review
- The NLRP3 molecule influences the therapeutic effects of mesenchymal stem cells through Glut1-mediated energy metabolic reprogramming.Journal of advanced research · 2024Article
- Mesenchymal stem cells as future treatment for cardiovascular regeneration and its challenges.Annals of translational medicine · 2024Review
- Current Strategies and Therapeutic Applications of Mesenchymal Stem Cell-Based Drug Delivery.Pharmaceuticals (Basel, Switzerland) · 2024Review
- Article
- Circulating Osteoprogenitor Cells Have a Mixed Immune and Mesenchymal Progenitor Function in Humans.Stem cells (Dayton, Ohio) · 2023Article
- The Dual Luminescence Lifetime pH/Oxygen Sensor: Evaluation of Applicability for Intravital Analysis of 2D- and 3D-Cultivated Human Endometrial Mesenchymal Stromal Cells.International journal of molecular sciences · 2023Article
- A scalable culture system incorporating microcarrier for specialised mesenchymal stem cells from human embryonic stem cells.Materials today. Bio · 2023Article
- Expansion and characterization of human limbus-derived stromal/mesenchymal stem cells in xeno-free medium for therapeutic applications.Stem cell research & therapy · 2023Article
- The Art of Stem Cell-Based Therapy.Advances in experimental medicine and biology · 2023Article
- Editorial: Immunomodulation of MSCs in tissue repairing and regeneration.Frontiers in immunology · 2023Article
- Physiologic isolation and expansion of human mesenchymal stem/stromal cells for manufacturing of cell-based therapy products.Engineering in life sciences · 2022Review
- Review
- Optimized Manufacture of Lyophilized Dermal Fibroblasts for Next-Generation Off-the-Shelf Progenitor Biological Bandages in Topical Post-Burn Regenerative Medicine.Biomedicines · 2021Article
- Article
- Viability, yield and expansion capability of feline MSCs obtained from subcutaneous and reproductive organ adipose depots.BMC veterinary research · 2021Article
- Innovative approaches for induction of gastrointestinal anastomotic healing: an update on experimental and clinical aspects.Langenbeck's archives of surgery · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Despite almost 50 years of research and over 20 years of preclinical and clinical studies, the question of curative potential of mesenchymal stem/stromal cells (MSCs) is still widely discussed in the scientific community. Non-reproducible treatment outcomes or even absence of treatment effects in comparison to control groups challenges the potential of these cells for routine application both in tissue engineering and in regenerative medicine. One of the reasons of such outcomes is non-standardized and often disadvantageous
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.